Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2928 + Almonertinib in Advanced NSCLC
NCT06585059Phase 1Not yet recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tqb2928 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Phase II recommended combination dose at 24 months, Objective Response Rate at 2 years and 3 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
tqb2928
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06585059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585059.